Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Development of ligands at γ-aminobutyrric acid type A (GABAA) receptor subtype as new agents for pain relief.

Guerrini G, Ciciani G, Bruni F, Selleri S, Martini C, Daniele S, Ghelardini C, Di Cesare Mannelli L, Costanzo A.

Bioorg Med Chem. 2011 Dec 15;19(24):7441-52. doi: 10.1016/j.bmc.2011.10.047. Epub 2011 Oct 21.

PMID:
22094278
2.

New fluoro derivatives of the pyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide system: evaluation of fluorine binding properties in the benzodiazepine site on γ-aminobutyrric acid type A (GABA(A)) receptor. Design, synthesis, biological, and molecular modeling investigation.

Guerrini G, Ciciani G, Bruni F, Selleri S, Guarino C, Melani F, Montali M, Daniele S, Martini C, Ghelardini C, Norcini M, Ciattini S, Costanzo A.

J Med Chem. 2010 Nov 11;53(21):7532-48. doi: 10.1021/jm1001887.

PMID:
20939501
3.

Piperazine imidazo[1,5-a]quinoxaline ureas as high-affinity GABAA ligands of dual functionality.

Jacobsen EJ, Stelzer LS, TenBrink RE, Belonga KL, Carter DB, Im HK, Im WB, Sethy VH, Tang AH, VonVoigtlander PF, Petke JD, Zhong WZ, Mickelson JW.

J Med Chem. 1999 Apr 8;42(7):1123-44.

PMID:
10197957
4.

Benzodiazepine receptor ligands. 8: synthesis and pharmacological evaluation of new pyrazolo[5,1-c] [1,2,4]benzotriazine 5-oxide 3- and 8-disubstituted: high affinity ligands endowed with inverse-agonist pharmacological efficacy.

Guerrini G, Costanzo A, Ciciani G, Bruni F, Selleri S, Costagli C, Besnard F, Costa B, Martini C, De Siena G, Malmberg-Aiello P.

Bioorg Med Chem. 2006 Feb 1;14(3):758-75. Epub 2005 Oct 7.

PMID:
16214350
5.

GABA A receptor subtype selectivity underlying selective anxiolytic effect of baicalin.

Wang F, Xu Z, Ren L, Tsang SY, Xue H.

Neuropharmacology. 2008 Dec;55(7):1231-7. doi: 10.1016/j.neuropharm.2008.07.040. Epub 2008 Aug 5.

PMID:
18723037
6.

RP 59037 and RP 60503: anxiolytic cyclopyrrolone derivatives with low sedative potential. interaction with the gamma-aminobutyric acidA/benzodiazepine receptor complex and behavioral effects in the rodent.

Doble A, Canton T, Dreisler S, Piot O, Boireau A, Stutzmann JM, Bardone MC, Rataud J, Roux M, Roussel G, et al.

J Pharmacol Exp Ther. 1993 Sep;266(3):1213-26.

PMID:
8103792
7.

New evidence that the pharmacological effects of benzodiazepine receptor ligands can be associated with activities at different BZ (omega) receptor subtypes.

Griebel G, Perrault G, Letang V, Granger P, Avenet P, Schoemaker H, Sanger DJ.

Psychopharmacology (Berl). 1999 Sep;146(2):205-13.

PMID:
10525757
8.

Benzodiazepine receptor ligands. 4. Synthesis and pharmacological evaluation of 3-heteroaryl-8-chloropyrazolo[5,1-c][1,2,4] benzotriazine 5-oxides.

Costanzo A, Guerrini G, Ciciani G, Bruni F, Selleri S, Costa B, Martini C, Lucacchini A, Aiello PM, Ipponi A.

J Med Chem. 1999 Jun 17;42(12):2218-26.

PMID:
10377227
9.

The CRF(1) receptor antagonist DMP696 produces anxiolytic effects and inhibits the stress-induced hypothalamic-pituitary-adrenal axis activation without sedation or ataxia in rats.

McElroy JF, Ward KA, Zeller KL, Jones KW, Gilligan PJ, He L, Lelas S.

Psychopharmacology (Berl). 2002 Dec;165(1):86-92. Epub 2002 Oct 12.

PMID:
12474122
10.

Medicinal chemistry of indolylglyoxylamide GABAA/BzR high affinity ligands: identification of novel anxiolytic/non sedative agents.

Salerno S, Da Settimo F, Taliani S, Simorini F, La Motta C, Fornaciari G, Marini AM.

Curr Top Med Chem. 2012;12(4):286-311. Review.

PMID:
22204484
11.

Discovery of imidazo[1,2-b][1,2,4]triazines as GABA(A) alpha2/3 subtype selective agonists for the treatment of anxiety.

Russell MG, Carling RW, Street LJ, Hallett DJ, Goodacre S, Mezzogori E, Reader M, Cook SM, Bromidge FA, Newman R, Smith AJ, Wafford KA, Marshall GR, Reynolds DS, Dias R, Ferris P, Stanley J, Lincoln R, Tye SJ, Sheppard WF, Sohal B, Pike A, Dominguez M, Atack JR, Castro JL.

J Med Chem. 2006 Feb 23;49(4):1235-8.

PMID:
16480260
12.

2-Phenyl-3H-imidazo[4,5-b]pyridine-3-acetamides as non-benzodiazepine anticonvulsants and anxiolytics.

Tomczuk BE, Taylor CR Jr, Moses LM, Sutherland DB, Lo YS, Johnson DN, Kinnier WB, Kilpatrick BF.

J Med Chem. 1991 Oct;34(10):2993-3006.

PMID:
1681105
13.

Novel 3-aroylpyrazolo[5,1-c][1,2,4]benzotriazine 5-oxides 8-substituted, ligands at GABAA/benzodiazepine receptor complex: synthesis, pharmacological and molecular modeling studies.

Guerrini G, Ciciani G, Cambi G, Bruni F, Selleri S, Melani F, Montali M, Martini C, Ghelardini C, Norcini M, Costanzo A.

Bioorg Med Chem. 2008 Apr 15;16(8):4471-89. doi: 10.1016/j.bmc.2008.02.058. Epub 2008 Mar 5.

PMID:
18325771
14.

Ligands for the benzodiazepine binding site--a survey.

Teuber L, Wätjens F, Jensen LH.

Curr Pharm Des. 1999 May;5(5):317-43. Review.

PMID:
10213798
15.

Ethyl 8-fluoro-6-(3-nitrophenyl)-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate as novel, highly potent, and safe antianxiety agent.

Anzini M, Braile C, Valenti S, Cappelli A, Vomero S, Marinelli L, Limongelli V, Novellino E, Betti L, Giannaccini G, Lucacchini A, Ghelardini C, Norcini M, Makovec F, Giorgi G, Ian Fryer R.

J Med Chem. 2008 Aug 14;51(15):4730-43. doi: 10.1021/jm8002944. Epub 2008 Jul 19.

PMID:
18637672
16.

GABAA receptors as targets for novel anxiolytic drugs.

Rupprecht R, Eser D, Zwanzger P, Möller HJ.

World J Biol Psychiatry. 2006;7(4):231-7. Review.

PMID:
17071543
17.

A synthetic non-benzodiazepine ligand for benzodiazepine receptors: a probe for investigating neuronal substrates of anxiety.

Lippa AS, Coupet J, Greenblatt EN, Klepner CA, Beer B.

Pharmacol Biochem Behav. 1979 Jul;11(1):99-106.

PMID:
40260
19.

The anxiolytic-like effects of the neurosteroid allopregnanolone: interactions with GABA(A) receptors.

Brot MD, Akwa Y, Purdy RH, Koob GF, Britton KT.

Eur J Pharmacol. 1997 Apr 23;325(1):1-7.

PMID:
9151931
20.

3-Heteroaryl-2-pyridones: benzodiazepine site ligands with functional delectivity for alpha 2/alpha 3-subtypes of human GABA(A) receptor-ion channels.

Collins I, Moyes C, Davey WB, Rowley M, Bromidge FA, Quirk K, Atack JR, McKernan RM, Thompson SA, Wafford K, Dawson GR, Pike A, Sohal B, Tsou NN, Ball RG, Castro JL.

J Med Chem. 2002 Apr 25;45(9):1887-900.

PMID:
11960500

Supplemental Content

Support Center